Investing Ideas
/
Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Results

0 new

Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.

2 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	TLX Telix Pharmaceuticals	AU$22.20	-3.1%	141.8%	AU$7.7b	AU$25.62	PE151.1x	E38.3%	n/a
	LGP Little Green Pharma	AU$0.13	0%	4.0%	AU$39.2m	AU$0.17	PS1.5x	E110.1%	n/a

Page 1 of 1